<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35806214</PMID><DateCompleted><Year>2022</Year><Month>07</Month><Day>12</Day></DateCompleted><DateRevised><Year>2024</Year><Month>08</Month><Day>31</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>13</Issue><PubDate><Year>2022</Year><Month>Jun</Month><Day>29</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>Long COVID: Association of Functional Autoantibodies against G-Protein-Coupled Receptors with an Impaired Retinal Microcirculation.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">7209</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms23137209</ELocationID><Abstract><AbstractText>Long COVID (LC) describes the clinical phenotype of symptoms after infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Diagnostic and therapeutic options are limited, as the pathomechanism of LC is elusive. As the number of acute SARS-CoV-2 infections was and is large, LC will be a challenge for the healthcare system. Previous studies revealed an impaired blood flow, the formation of microclots, and autoimmune mechanisms as potential factors in this complex interplay. Since functionally active autoantibodies against G-protein-coupled receptors (GPCR-AAbs) were observed in patients after SARS-CoV-2 infection, this study aimed to correlate the appearance of GPCR-AAbs with capillary microcirculation. The seropositivity of GPCR-AAbs was measured by an established cardiomyocyte bioassay in 42 patients with LC and 6 controls. Retinal microcirculation was measured by OCT-angiography and quantified as macula and peripapillary vessel density (VD) by the Erlangen-Angio Tool. A statistical analysis yielded impaired VD in patients with LC compared to the controls, which was accentuated in female persons. A significant decrease in macula and peripapillary VD for AAbs targeting adrenergic &#x3b2;2-receptor, MAS-receptor angiotensin-II-type-1 receptor, and adrenergic &#x3b1;1-receptor were observed. The present study might suggest that a seropositivity of GPCR-AAbs can be linked to an impaired retinal capillary microcirculation, potentially mirroring the systemic microcirculation with consecutive clinical symptoms.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Szewczykowski</LastName><ForeName>Charlotte</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Universit&#xe4;tsklinikum Erlangen, Friedrich-Alexander-Universit&#xe4;t Erlangen-N&#xfc;rnberg, 91054 Erlangen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mardin</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Universit&#xe4;tsklinikum Erlangen, Friedrich-Alexander-Universit&#xe4;t Erlangen-N&#xfc;rnberg, 91054 Erlangen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lucio</LastName><ForeName>Marianna</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Research Unit Analytical BioGeoChemistry, Helmholtz Zentrum M&#xfc;nchen-German Research Center for Environmental Health, 85764 Neuherberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wallukat</LastName><ForeName>Gerd</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Berlin Cures GmbH, 10719 Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hoffmanns</LastName><ForeName>Jakob</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Universit&#xe4;tsklinikum Erlangen, Friedrich-Alexander-Universit&#xe4;t Erlangen-N&#xfc;rnberg, 91054 Erlangen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schr&#xf6;der</LastName><ForeName>Thora</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Universit&#xe4;tsklinikum Erlangen, Friedrich-Alexander-Universit&#xe4;t Erlangen-N&#xfc;rnberg, 91054 Erlangen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raith</LastName><ForeName>Franziska</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Universit&#xe4;tsklinikum Erlangen, Friedrich-Alexander-Universit&#xe4;t Erlangen-N&#xfc;rnberg, 91054 Erlangen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rogge</LastName><ForeName>Lennart</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Universit&#xe4;tsklinikum Erlangen, Friedrich-Alexander-Universit&#xe4;t Erlangen-N&#xfc;rnberg, 91054 Erlangen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heltmann</LastName><ForeName>Felix</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Universit&#xe4;tsklinikum Erlangen, Friedrich-Alexander-Universit&#xe4;t Erlangen-N&#xfc;rnberg, 91054 Erlangen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moritz</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Universit&#xe4;tsklinikum Erlangen, Friedrich-Alexander-Universit&#xe4;t Erlangen-N&#xfc;rnberg, 91054 Erlangen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beitlich</LastName><ForeName>Lorenz</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Universit&#xe4;tsklinikum Erlangen, Friedrich-Alexander-Universit&#xe4;t Erlangen-N&#xfc;rnberg, 91054 Erlangen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schottenhamml</LastName><ForeName>Julia</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Universit&#xe4;tsklinikum Erlangen, Friedrich-Alexander-Universit&#xe4;t Erlangen-N&#xfc;rnberg, 91054 Erlangen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Herrmann</LastName><ForeName>Martin</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-0258-2484</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine 3, Universit&#xe4;tsklinikum Erlangen, Friedrich-Alexander-Universit&#xe4;t Erlangen-N&#xfc;rnberg, 91054 Erlangen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Deutsches Zentrum f&#xfc;r Immuntherapie (DZI), Friedrich-Alexander-Universit&#xe4;t Erlangen-N&#xfc;rnberg (FAU) and Universit&#xe4;tsklinikum Erlangen, 91054 Erlangen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harrer</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0001-6945-3241</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine 3, Universit&#xe4;tsklinikum Erlangen, Friedrich-Alexander-Universit&#xe4;t Erlangen-N&#xfc;rnberg, 91054 Erlangen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Deutsches Zentrum f&#xfc;r Immuntherapie (DZI), Friedrich-Alexander-Universit&#xe4;t Erlangen-N&#xfc;rnberg (FAU) and Universit&#xe4;tsklinikum Erlangen, 91054 Erlangen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ganslmayer</LastName><ForeName>Marion</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine 1, Universit&#xe4;t of Erlangen-N&#xfc;rnberg, Friedrich-Alexander-Universit&#xe4;t Erlangen-N&#xfc;rnberg, 91054 Erlangen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kruse</LastName><ForeName>Friedrich E</ForeName><Initials>FE</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Universit&#xe4;tsklinikum Erlangen, Friedrich-Alexander-Universit&#xe4;t Erlangen-N&#xfc;rnberg, 91054 Erlangen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kr&#xe4;ter</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Max Planck Institute for the Science of Light &amp; Max-Planck-Zentrum f&#xfc;r Physik und Medizin, 91058 Erlangen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guck</LastName><ForeName>Jochen</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Max Planck Institute for the Science of Light &amp; Max-Planck-Zentrum f&#xfc;r Physik und Medizin, 91058 Erlangen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>L&#xe4;mmer</LastName><ForeName>Robert</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-6294-0730</Identifier><AffiliationInfo><Affiliation>Department of Ophthalmology, Universit&#xe4;tsklinikum Erlangen, Friedrich-Alexander-Universit&#xe4;t Erlangen-N&#xfc;rnberg, 91054 Erlangen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zenkel</LastName><ForeName>Matthias</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-0141-120X</Identifier><AffiliationInfo><Affiliation>Department of Ophthalmology, Universit&#xe4;tsklinikum Erlangen, Friedrich-Alexander-Universit&#xe4;t Erlangen-N&#xfc;rnberg, 91054 Erlangen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gie&#xdf;l</LastName><ForeName>Andreas</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-9768-2049</Identifier><AffiliationInfo><Affiliation>Department of Ophthalmology, Universit&#xe4;tsklinikum Erlangen, Friedrich-Alexander-Universit&#xe4;t Erlangen-N&#xfc;rnberg, 91054 Erlangen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hohberger</LastName><ForeName>Bettina</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0002-2546-5504</Identifier><AffiliationInfo><Affiliation>Department of Ophthalmology, Universit&#xe4;tsklinikum Erlangen, Friedrich-Alexander-Universit&#xe4;t Erlangen-N&#xfc;rnberg, 91054 Erlangen, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>01EP2108A</GrantID><Agency>Federal Ministry of Education and Research</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>06</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018663">Adrenergic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001323">Autoantibodies</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D043562">Receptors, G-Protein-Coupled</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D018663" MajorTopicYN="N">Adrenergic Agents</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001323" MajorTopicYN="N">Autoantibodies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008833" MajorTopicYN="N">Microcirculation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D043562" MajorTopicYN="N">Receptors, G-Protein-Coupled</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012171" MajorTopicYN="N">Retinal Vessels</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D041623" MajorTopicYN="N">Tomography, Optical Coherence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Long-COVID syndrome</Keyword><Keyword MajorTopicYN="N">OCT&#x2013;angiography</Keyword><Keyword MajorTopicYN="N">chronic fatigue syndrome</Keyword><Keyword MajorTopicYN="N">functionally GPCR autoantibodies</Keyword><Keyword MajorTopicYN="N">glaucoma</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest in the present topic of the study. Hohberger B (Heidelberg Engineering), Harrer T (none), Kruse F (none), Hoffmanns J (none), Rogge L (none), Heltmann F (none), Moritz M (none), Beitlich L (none), Lucio M (none), Szewczykowski C (none), Schottenhamml J (none), Bergua A (none), Zenkel M (none), Gie&#xdf;l A (none), Schl&#xf6;tzer-Schrehardt U, L&#xe4;mmer R (none), Herrmann M (none), Wallukat G (employed by Berlin Cures GmbH, shareholders of Berlin Cures Holding AG, the holding company of Berlin Cures), Mardin C (Heidelberg Engineering), Kr&#xe4;ter M (none), Guck J (none).</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>5</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>6</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>6</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>7</Month><Day>9</Day><Hour>1</Hour><Minute>12</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>7</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>7</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>6</Month><Day>29</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35806214</ArticleId><ArticleId IdType="pmc">PMC9266742</ArticleId><ArticleId IdType="doi">10.3390/ijms23137209</ArticleId><ArticleId IdType="pii">ijms23137209</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organisation  Novel Coronavirus (2019-nCoV) Situation Report-1.  [(accessed on 18 February 2022)]; Available online:  https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200121-sitrep-1-2019-ncov.pdf?sfvrsn=20a99c10_4.</Citation></Reference><Reference><Citation>World Health Organisation  Listing of WHO&#x2019;s Response to COVID-19.  [(accessed on 18 February 2022)]; Available online:  https://www.who.int/news/item/29-06-2020-covidtimeline.</Citation></Reference><Reference><Citation>World Health Organisation  WHO Coronavirus (COVID-19) Dashbord.  [(accessed on 18 February 2022)]; Available online:  https://covid19.who.int/</Citation></Reference><Reference><Citation>Ludvigsson J.F. Case report and systematic review suggest that children may experience similar long-term effects to adults after clinical COVID-19. Acta Paediatr. 2021;110:914&#x2013;921. doi: 10.1111/apa.15673.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apa.15673</ArticleId><ArticleId IdType="pmc">PMC7753397</ArticleId><ArticleId IdType="pubmed">33205450</ArticleId></ArticleIdList></Reference><Reference><Citation>Townsend L., Dyer A.H., Jones K., Dunne J., Mooney A., Gaffney F., O&#x2019;Connor L., Leavy D., O&#x2019;Brien K., Dowds J., et al. Persistent fatigue following SARS-CoV-2 infection is common and independent of severity of initial infection. PLoS ONE. 2020;15:e0240784. doi: 10.1371/journal.pone.0240784.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0240784</ArticleId><ArticleId IdType="pmc">PMC7652254</ArticleId><ArticleId IdType="pubmed">33166287</ArticleId></ArticleIdList></Reference><Reference><Citation>Dennis A., Wamil M., Alberts J., Oben J., Cuthbertson D.J., Wootton D., Crooks M., Gabbay M., Brady M., Hishmeh L., et al. Multiorgan impairment in low-risk individuals with post-COVID-19 syndrome: A prospective, community-based study. BMJ Open. 2021;11:e048391. doi: 10.1136/bmjopen-2020-048391.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2020-048391</ArticleId><ArticleId IdType="pmc">PMC8727683</ArticleId><ArticleId IdType="pubmed">33785495</ArticleId></ArticleIdList></Reference><Reference><Citation>Blomberg B., Mohn K.G.-I., Brokstad K.A., Zhou F., Linchausen D.W., Hansen B.-A., Lartey S., Onyango T.B., Kuwelker K., S&#xe6;vik M., et al. Long COVID in a prospective cohort of home-isolated patients. Nat. Med. 2021;27:1607&#x2013;1613. doi: 10.1038/s41591-021-01433-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01433-3</ArticleId><ArticleId IdType="pmc">PMC8440190</ArticleId><ArticleId IdType="pubmed">34163090</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis H.E., Assaf G.S., McCorkell L., Wei H., Low R.J., Re&#x2019;em Y., Redfield S., Austin J.P., Akrami A. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine. 2021;38:101019. doi: 10.1016/j.eclinm.2021.101019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2021.101019</ArticleId><ArticleId IdType="pmc">PMC8280690</ArticleId><ArticleId IdType="pubmed">34308300</ArticleId></ArticleIdList></Reference><Reference><Citation>St&#xe5;hlberg M., Reistam U., Fedorowski A., Villacorta H., Horiuchi Y., Bax J., Pitt B., Matskeplishvili S., L&#xfc;scher T.F., Weichert I., et al. Post-COVID-19 Tachycardia Syndrome: A Distinct Phenotype of Post-Acute COVID-19 Syndrome. Am. J. Med. 2021;134:1451&#x2013;1456. doi: 10.1016/j.amjmed.2021.07.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjmed.2021.07.004</ArticleId><ArticleId IdType="pmc">PMC8356730</ArticleId><ArticleId IdType="pubmed">34390682</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudre C.H., Murray B., Varsavsky T., Graham M.S., Penfold R.S., Bowyer R.C., Pujol J.C., Klaser K., Antonelli M., Canas L.S., et al. Attributes and predictors of long COVID. Nat. Med. 2021;27:626&#x2013;631. doi: 10.1038/s41591-021-01292-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01292-y</ArticleId><ArticleId IdType="pmc">PMC7611399</ArticleId><ArticleId IdType="pubmed">33692530</ArticleId></ArticleIdList></Reference><Reference><Citation>Dotan A., Muller S., Kanduc D., David P., Halpert G., Shoenfeld Y. The SARS-CoV-2 as an instrumental trigger of autoimmunity. Autoimmun. Rev. 2021;20:102792. doi: 10.1016/j.autrev.2021.102792.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2021.102792</ArticleId><ArticleId IdType="pmc">PMC7892316</ArticleId><ArticleId IdType="pubmed">33610751</ArticleId></ArticleIdList></Reference><Reference><Citation>Hohberger B., Harrer T., Mardin C., Kruse F., Hoffmanns J., Rogge L., Heltmann F., Moritz M., Szewczykowski C., Schottenhamml J., et al. Case Report: Neutralization of Autoantibodies Targeting G-Protein-Coupled Receptors Improves Capillary Impairment and Fatigue Symptoms after COVID-19 Infection. Front. Med. 2021;8:2008. doi: 10.3389/fmed.2021.754667.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2021.754667</ArticleId><ArticleId IdType="pmc">PMC8637609</ArticleId><ArticleId IdType="pubmed">34869451</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallukat G., Hohberger B., Wenzel K., F&#xfc;rst J., Schulze-Rothe S., Wallukat A., H&#xf6;nicke A.-S., M&#xfc;ller J. Functional autoantibodies against G-protein coupled receptors in patients with persistent Long-COVID-19 symptoms. J. Transl. Autoimmun. 2021;4:100100. doi: 10.1016/j.jtauto.2021.100100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtauto.2021.100100</ArticleId><ArticleId IdType="pmc">PMC8049853</ArticleId><ArticleId IdType="pubmed">33880442</ArticleId></ArticleIdList></Reference><Reference><Citation>Fogarty H., Townsend L., Morrin H., Ahmad A., Comerford C., Karampini E., Englert H., Byrne M., Bergin C., O&#x2019;Sullivan J.M., et al. Persistent endotheliopathy in the pathogenesis of long COVID syndrome. J. Thromb. Haemost. 2021;19:2546&#x2013;2553. doi: 10.1111/jth.15490.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.15490</ArticleId><ArticleId IdType="pmc">PMC8420256</ArticleId><ArticleId IdType="pubmed">34375505</ArticleId></ArticleIdList></Reference><Reference><Citation>Ambrosino P., Calcaterra I., Molino A., Moretta P., Lupoli R., Spedicato G.A., Papa A., Motta A., Maniscalco M., Di Minno M.N.D. Persistent Endothelial Dysfunction in Post-Acute COVID-19 Syndrome: A Case-Control Study. Biomedicines. 2021;9:957. doi: 10.3390/biomedicines9080957.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines9080957</ArticleId><ArticleId IdType="pmc">PMC8391623</ArticleId><ArticleId IdType="pubmed">34440161</ArticleId></ArticleIdList></Reference><Reference><Citation>Varga Z., Flammer A.J., Steiger P., Haberecker M., Andermatt R., Zinkernagel A.S., Mehra M.R., Schuepbach R.A., Ruschitzka F., Moch H. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395:1417&#x2013;1418. doi: 10.1016/S0140-6736(20)30937-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30937-5</ArticleId><ArticleId IdType="pmc">PMC7172722</ArticleId><ArticleId IdType="pubmed">32325026</ArticleId></ArticleIdList></Reference><Reference><Citation>Hohberger B., Ganslmayer M., Lucio M., Kruse F., Hoffmanns J., Moritz M., Rogge L., Heltmann F., Szewczykowski C., F&#xfc;rst J., et al. Retinal Microcirculation as a Correlate of a Systemic Capillary Impairment after Severe Acute Respiratory Syndrome Coronavirus 2 Infection. Front. Med. 2021;8:676554. doi: 10.3389/fmed.2021.676554.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2021.676554</ArticleId><ArticleId IdType="pmc">PMC8299003</ArticleId><ArticleId IdType="pubmed">34307408</ArticleId></ArticleIdList></Reference><Reference><Citation>Pretorius E., Vlok M., Venter C., Bezuidenhout J.A., Laubscher G.J., Steenkamp J., Kell D.B. Persistent clotting protein pathology in Long COVID/Post-Acute Sequelae of COVID-19 (PASC) is accompanied by increased levels of antiplasmin. Cardiovasc. Diabetol. 2021;20:172. doi: 10.1186/s12933-021-01359-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12933-021-01359-7</ArticleId><ArticleId IdType="pmc">PMC8381139</ArticleId><ArticleId IdType="pubmed">34425843</ArticleId></ArticleIdList></Reference><Reference><Citation>Leppkes M., Knopf J., Naschberger E., Lindemann A., Singh J., Herrmann I., St&#xfc;rzl M., Staats L., Mahajan A., Schauer C., et al. Vascular occlusion by neutrophil extracellular traps in COVID-19. EBioMedicine. 2020;58:102925. doi: 10.1016/j.ebiom.2020.102925.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2020.102925</ArticleId><ArticleId IdType="pmc">PMC7397705</ArticleId><ArticleId IdType="pubmed">32745993</ArticleId></ArticleIdList></Reference><Reference><Citation>Ackermann M., Anders H.J., Bilyy R., Bowlin G.L., Daniel C., De Lorenzo R., Egeblad M., Henneck T., Hidalgo A., Hoffmann M., et al. Patients with COVID-19: In the dark-NETs of neutrophils. Cell Death Differ. 2021;28:3125&#x2013;3139. doi: 10.1038/s41418-021-00805-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41418-021-00805-z</ArticleId><ArticleId IdType="pmc">PMC8142290</ArticleId><ArticleId IdType="pubmed">34031543</ArticleId></ArticleIdList></Reference><Reference><Citation>Wyl&#x119;ga&#x142;a A., Teper S., Dobrowolski D., Wyl&#x119;ga&#x142;a E. Optical coherence angiography: A review. Medicine. 2016;95:e4907. doi: 10.1097/MD.0000000000004907.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000004907</ArticleId><ArticleId IdType="pmc">PMC5072931</ArticleId><ArticleId IdType="pubmed">27741104</ArticleId></ArticleIdList></Reference><Reference><Citation>Hohberger B., Mardin C.Y. OCT Angiography as an Interdisciplinary Diagnostic Tool for Systemic Diseases. Klin. Monbl. Augenheilkd. 2021;238:1294&#x2013;1298. doi: 10.1055/a-1654-0504.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/a-1654-0504</ArticleId><ArticleId IdType="pubmed">34879428</ArticleId></ArticleIdList></Reference><Reference><Citation>Abrishami M., Emamverdian Z., Shoeibi N., Omidtabrizi A., Daneshvar R., Saeidi Rezvani T., Saeedian N., Eslami S., Mazloumi M., Sadda S., et al. Optical coherence tomography angiography analysis of the retina in patients recovered from COVID-19: A case-control study. Can. J. Ophthalmol. 2021;56:24&#x2013;30. doi: 10.1016/j.jcjo.2020.11.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcjo.2020.11.006</ArticleId><ArticleId IdType="pmc">PMC7666612</ArticleId><ArticleId IdType="pubmed">33249111</ArticleId></ArticleIdList></Reference><Reference><Citation>Jidigam V.K., Singh R., Batoki J.C., Milliner C., Sawant O.B., Bonilha V.L., Rao S. Histopathological assessments reveal retinal vascular changes, inflammation and gliosis in patients with lethal COVID-19. medRxiv. 2021 doi: 10.1007/s00417-021-05460-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00417-021-05460-1</ArticleId><ArticleId IdType="pmc">PMC8553591</ArticleId><ArticleId IdType="pubmed">34714382</ArticleId></ArticleIdList></Reference><Reference><Citation>J&#xfc;nemann A., Hohberger B., Rech J., Sheriff A., Fu Q., Schl&#xf6;tzer-Schrehardt U., Voll R.E., Bartel S., Kalbacher H., Hoebeke J., et al. Agonistic Autoantibodies to the &#x3b2;2-Adrenergic Receptor Involved in the Pathogenesis of Open-Angle Glaucoma. Front. Immunol. 2018;9:145. doi: 10.3389/fimmu.2018.00145.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.00145</ArticleId><ArticleId IdType="pmc">PMC5816038</ArticleId><ArticleId IdType="pubmed">29483909</ArticleId></ArticleIdList></Reference><Reference><Citation>Loebel M., Grabowski P., Heidecke H., Bauer S., Hanitsch L.G., Wittke K., Meisel C., Reinke P., Volk H.D., Fluge &#xd8;., et al. Antibodies to &#x3b2; adrenergic and muscarinic cholinergic receptors in patients with Chronic Fatigue Syndrome. Brain Behav. Immun. 2016;52:32&#x2013;39. doi: 10.1016/j.bbi.2015.09.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2015.09.013</ArticleId><ArticleId IdType="pubmed">26399744</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallukat G., Nissen E., Morwinski R., M&#xfc;ller J. Autoantibodies against the beta- and muscarinic receptors in cardiomyopathy. Herz. 2000;25:261&#x2013;266. doi: 10.1007/s000590050017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s000590050017</ArticleId><ArticleId IdType="pubmed">10904849</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallukat G., Neichel D., Nissen E., Homuth V., Luft F.C. Agonistic autoantibodies directed against the angiotensin II AT1 receptor in patients with preeclampsia. Can. J. Physiol. Pharmacol. 2003;81:79&#x2013;83. doi: 10.1139/y02-160.</Citation><ArticleIdList><ArticleId IdType="doi">10.1139/y02-160</ArticleId><ArticleId IdType="pubmed">12710518</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organisation  A Clinical Case Definition of Post COVID-19 Condition by a Delphi Consensus.  [(accessed on 4 April 2022)];2021 October 6; Available online:  https://www.who.int/publications/i/item/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8691845</ArticleId><ArticleId IdType="pubmed">34951953</ArticleId></ArticleIdList></Reference><Reference><Citation>Darif D., Hammi I., Kihel A., El Idrissi Saik I., Guessous F., Akarid K. The pro-inflammatory cytokines in COVID-19 pathogenesis: What goes wrong? Microb. Pathog. 2021;153:104799. doi: 10.1016/j.micpath.2021.104799.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.micpath.2021.104799</ArticleId><ArticleId IdType="pmc">PMC7889464</ArticleId><ArticleId IdType="pubmed">33609650</ArticleId></ArticleIdList></Reference><Reference><Citation>Unal H., Jagannathan R., Karnik S.S. Mechanism of GPCR-directed autoantibodies in diseases. Adv. Exp. Med. Biol. 2012;749:187&#x2013;199. doi: 10.1007/978-1-4614-3381-1_13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-4614-3381-1_13</ArticleId><ArticleId IdType="pubmed">22695846</ArticleId></ArticleIdList></Reference><Reference><Citation>Walls A.C., Park Y.J., Tortorici M.A., Wall A., McGuire A.T., Veesler D. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell. 2020;181:281&#x2013;292.e6. doi: 10.1016/j.cell.2020.02.058.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.02.058</ArticleId><ArticleId IdType="pmc">PMC7102599</ArticleId><ArticleId IdType="pubmed">32155444</ArticleId></ArticleIdList></Reference><Reference><Citation>Li M.Y., Li L., Zhang Y., Wang X.S. Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues. Infect. Dis. Poverty. 2020;9:45. doi: 10.1186/s40249-020-00662-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40249-020-00662-x</ArticleId><ArticleId IdType="pmc">PMC7186534</ArticleId><ArticleId IdType="pubmed">32345362</ArticleId></ArticleIdList></Reference><Reference><Citation>Guney C., Akar F. Epithelial and Endothelial Expressions of ACE2: SARS-CoV-2 Entry Routes. J. Pharm. Pharm. Sci. 2021;24:84&#x2013;93. doi: 10.18433/jpps31455.</Citation><ArticleIdList><ArticleId IdType="doi">10.18433/jpps31455</ArticleId><ArticleId IdType="pubmed">33626315</ArticleId></ArticleIdList></Reference><Reference><Citation>Simoes e Silva A.C., Silveira K.D., Ferreira A.J., Teixeira M.M. ACE2, angiotensin-(1&#x2013;7) and Mas receptor axis in inflammation and fibrosis. Br. J. Pharmacol. 2013;169:477&#x2013;492. doi: 10.1111/bph.12159.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bph.12159</ArticleId><ArticleId IdType="pmc">PMC3682698</ArticleId><ArticleId IdType="pubmed">23488800</ArticleId></ArticleIdList></Reference><Reference><Citation>Meixiong J., Anderson M., Limjunyawong N., Sabbagh M.F., Hu E., Mack M.R., Oetjen L.K., Wang F., Kim B.S., Dong X. Activation of Mast-Cell-Expressed Mas-Related G-Protein-Coupled Receptors Drives Non-histaminergic Itch. Immunity. 2019;50:1163&#x2013;1171.e5. doi: 10.1016/j.immuni.2019.03.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2019.03.013</ArticleId><ArticleId IdType="pmc">PMC6531358</ArticleId><ArticleId IdType="pubmed">31027996</ArticleId></ArticleIdList></Reference><Reference><Citation>Serhan N., Cenac N., Basso L., Gaudenzio N. Mas-related G protein-coupled receptors (Mrgprs)&#x2013;Key regulators of neuroimmune interactions. Neurosci. Lett. 2021;749:135724. doi: 10.1016/j.neulet.2021.135724.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2021.135724</ArticleId><ArticleId IdType="pubmed">33600909</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong X., Han S.-K., Zylka M.J., Simon M.I., Anderson D.J. A Diverse Family of GPCRs Expressed in Specific Subsets of Nociceptive Sensory Neurons. Cell. 2001;106:619&#x2013;632. doi: 10.1016/S0092-8674(01)00483-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0092-8674(01)00483-4</ArticleId><ArticleId IdType="pubmed">11551509</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramanian H., Gupta K., Guo Q., Price R., Ali H. Mas-related gene X2 (MrgX2) is a novel G protein-coupled receptor for the antimicrobial peptide LL-37 in human mast cells: Resistance to receptor phosphorylation, desensitization, and internalization. J. Biol. Chem. 2011;286:44739&#x2013;44749. doi: 10.1074/jbc.M111.277152.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M111.277152</ArticleId><ArticleId IdType="pmc">PMC3247983</ArticleId><ArticleId IdType="pubmed">22069323</ArticleId></ArticleIdList></Reference><Reference><Citation>Robas N., Mead E., Fidock M. MrgX2 is a high potency cortistatin receptor expressed in dorsal root ganglion. J. Biol. Chem. 2003;278:44400&#x2013;44404. doi: 10.1074/jbc.M302456200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M302456200</ArticleId><ArticleId IdType="pubmed">12915402</ArticleId></ArticleIdList></Reference><Reference><Citation>Lautner R.Q., Villela D.C., Fraga-Silva R.A., Silva N., Verano-Braga T., Costa-Fraga F., Jankowski J., Jankowski V., Sousa F., Alzamora A., et al. Discovery and characterization of alamandine: A novel component of the renin-angiotensin system. Circ. Res. 2013;112:1104&#x2013;1111. doi: 10.1161/CIRCRESAHA.113.301077.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCRESAHA.113.301077</ArticleId><ArticleId IdType="pubmed">23446738</ArticleId></ArticleIdList></Reference><Reference><Citation>Verdecchia P., Cavallini C., Spanevello A., Angeli F. The pivotal link between ACE2 deficiency and SARS-CoV-2 infection. Eur. J. Intern. Med. 2020;76:14&#x2013;20. doi: 10.1016/j.ejim.2020.04.037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejim.2020.04.037</ArticleId><ArticleId IdType="pmc">PMC7167588</ArticleId><ArticleId IdType="pubmed">32336612</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y.H., Zhang Y.H., Dong X.F., Hao Q.Q., Zhou X.M., Yu Q.T., Li S.Y., Chen X., Tengbeh A.F., Dong B., et al. ACE2 and Ang-(1&#x2013;7) protect endothelial cell function and prevent early atherosclerosis by inhibiting inflammatory response. Inflamm. Res. 2015;64:253&#x2013;260. doi: 10.1007/s00011-015-0805-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00011-015-0805-1</ArticleId><ArticleId IdType="pubmed">25721616</ArticleId></ArticleIdList></Reference><Reference><Citation>Douillette A., Bibeau-Poirier A., Gravel S.P., Cl&#xe9;ment J.F., Ch&#xe9;nard V., Moreau P., Servant M.J. The proinflammatory actions of angiotensin II are dependent on p65 phosphorylation by the IkappaB kinase complex. J. Biol. Chem. 2006;281:13275&#x2013;13284. doi: 10.1074/jbc.M512815200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M512815200</ArticleId><ArticleId IdType="pubmed">16513650</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao Y.H., Wei Y.M., Wang M., Wang Z.H., Yuan H.T., Cheng L.X. Autoantibodies against AT1-receptor and alpha1-adrenergic receptor in patients with hypertension. Hypertens Res. 2002;25:641&#x2013;646. doi: 10.1291/hypres.25.641.</Citation><ArticleIdList><ArticleId IdType="doi">10.1291/hypres.25.641</ArticleId><ArticleId IdType="pubmed">12358154</ArticleId></ArticleIdList></Reference><Reference><Citation>Okruhlicova L., Morwinski R., Schulze W., Bartel S., Weismann P., Tribulova N., Wallukat G. Autoantibodies against G-protein-coupled receptors modulate heart mast cells. Cell Mol. Immunol. 2007;4:127&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pubmed">17484807</ArticleId></ArticleIdList></Reference><Reference><Citation>Afrin L.B., Weinstock L.B., Molderings G.J. Covid-19 hyperinflammation and post-Covid-19 illness may be rooted in mast cell activation syndrome. Int. J. Infect. Dis. 2020;100:327&#x2013;332. doi: 10.1016/j.ijid.2020.09.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2020.09.016</ArticleId><ArticleId IdType="pmc">PMC7529115</ArticleId><ArticleId IdType="pubmed">32920235</ArticleId></ArticleIdList></Reference><Reference><Citation>Haberland A., Santos R.A., Schimke I., Wallukat G. Are Agonistic Autoantibodies against G-Protein Coupled Receptors Involved in the Development of Long-Term Side Effects of Tumor Chemotherapy? Case Rep. Oncol. 2013;6:104&#x2013;108. doi: 10.1159/000348425.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000348425</ArticleId><ArticleId IdType="pmc">PMC3618042</ArticleId><ArticleId IdType="pubmed">23569443</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka S., Kuratsune H., Hidaka Y., Hakariya Y., Tatsumi K.I., Takano T., Kanakura Y., Amino N. Autoantibodies against muscarinic cholinergic receptor in chronic fatigue syndrome. Int. J. Mol. Med. 2003;12:225&#x2013;230. doi: 10.3892/ijmm.12.2.225.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/ijmm.12.2.225</ArticleId><ArticleId IdType="pubmed">12851722</ArticleId></ArticleIdList></Reference><Reference><Citation>Gunning W.T., 3rd, Kvale H., Kramer P.M., Karabin B.L., Grubb B.P. Postural Orthostatic Tachycardia Syndrome Is Associated With Elevated G-Protein Coupled Receptor Autoantibodies. J. Am. Heart Assoc. 2019;8:e013602. doi: 10.1161/JAHA.119.013602.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/JAHA.119.013602</ArticleId><ArticleId IdType="pmc">PMC6818019</ArticleId><ArticleId IdType="pubmed">31495251</ArticleId></ArticleIdList></Reference><Reference><Citation>Kharraziha I., Axelsson J., Ricci F., Di Martino G., Persson M., Sutton R., Fedorowski A., Hamrefors V. Serum Activity against G Protein-Coupled Receptors and Severity of Orthostatic Symptoms in Postural Orthostatic Tachycardia Syndrome. J. Am. Heart Assoc. 2020;9:e015989. doi: 10.1161/JAHA.120.015989.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/JAHA.120.015989</ArticleId><ArticleId IdType="pmc">PMC7792263</ArticleId><ArticleId IdType="pubmed">32750291</ArticleId></ArticleIdList></Reference><Reference><Citation>Hosari S., Hohberger B., Theelke L., Sari H., Lucio M., Mardin C.Y. OCT Angiography: Measurement of Retinal Macular Microvasculature with Spectralis II OCT Angiography-Reliability and Reproducibility. Ophthalmologica. 2020;243:75&#x2013;84. doi: 10.1159/000502458.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000502458</ArticleId><ArticleId IdType="pubmed">31509842</ArticleId></ArticleIdList></Reference><Reference><Citation>Meinke M., M&#xfc;ller G., Helfmann J., Friebel M. Optical properties of platelets and blood plasma and their influence on the optical behavior of whole blood in the visible to.....o near infrared wavelength range. J. Biomed. Opt. 2007;12:014024. doi: 10.1117/1.2435177.</Citation><ArticleIdList><ArticleId IdType="doi">10.1117/1.2435177</ArticleId><ArticleId IdType="pubmed">17343499</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu J., Merkle C.W., Bernucci M.T., Chong S.P., Srinivasan V.J. Can OCT Angiography Be Made a Quantitative Blood Measurement Tool? Appl. Sci. 2017;7:687. doi: 10.3390/app7070687.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/app7070687</ArticleId><ArticleId IdType="pmc">PMC6042878</ArticleId><ArticleId IdType="pubmed">30009045</ArticleId></ArticleIdList></Reference><Reference><Citation>Faber D.J., Aalders M.C., Mik E.G., Hooper B.A., van Gemert M.J., van Leeuwen T.G. Oxygen saturation-dependent absorption and scattering of blood. Phys. Rev. Lett. 2004;93:028102. doi: 10.1103/PhysRevLett.93.028102.</Citation><ArticleIdList><ArticleId IdType="doi">10.1103/PhysRevLett.93.028102</ArticleId><ArticleId IdType="pubmed">15323954</ArticleId></ArticleIdList></Reference><Reference><Citation>Luhtala S., Vaajanen A., Oksala O., Valjakka J., Vapaatalo H. Activities of angiotensin-converting enzymes ACE1 and ACE2 and inhibition by bioactive peptides in porcine ocular tissues. J. Ocul. Pharmacol. Ther. Off. J. Assoc. Ocul. Pharmacol. Ther. 2009;25:23&#x2013;28. doi: 10.1089/jop.2008.0081.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/jop.2008.0081</ArticleId><ArticleId IdType="pubmed">19232015</ArticleId></ArticleIdList></Reference><Reference><Citation>Hendrickson J.E., Hendrickson E.T., Gehrie E.A., Sidhu D., Wallukat G., Schimke I., Tormey C.A. Complex regional pain syndrome and dysautonomia in a 14-year-old girl responsive to therapeutic plasma exchange. J. Clin. Apher. 2016;31:368&#x2013;374. doi: 10.1002/jca.21407.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jca.21407</ArticleId><ArticleId IdType="pubmed">26011726</ArticleId></ArticleIdList></Reference><Reference><Citation>T&#xf6;lle M., Freitag H., Antelmann M., Hartwig J., Schuchardt M., van der Giet M., Eckardt K.U., Grabowski P., Scheibenbogen C. Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Efficacy of Repeat Immunoadsorption. J. Clin. Med. 2020;9:2443. doi: 10.3390/jcm9082443.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm9082443</ArticleId><ArticleId IdType="pmc">PMC7465279</ArticleId><ArticleId IdType="pubmed">32751659</ArticleId></ArticleIdList></Reference><Reference><Citation>Pitarokoili K., Maier A., de Moya Rubio E.C., Hahn K., Wallukat G., Athanasopoulos D., Gr&#xfc;ter T., Motte J., Fisse A.L., Gold R. Maintenance therapy with subcutaneous immunoglobulin in a patient with immune-mediated neuropathic postural tachycardia syndrome. J. Transl. Autoimmun. 2021;4:100112. doi: 10.1016/j.jtauto.2021.100112.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtauto.2021.100112</ArticleId><ArticleId IdType="pmc">PMC8387908</ArticleId><ArticleId IdType="pubmed">34471867</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrari I., Levin M.J., Wallukat G., Elies R., Lebesgue D., Chiale P., Elizari M., Rosenbaum M., Hoebeke J. Molecular mimicry between the immunodominant ribosomal protein P0 of Trypanosoma cruzi and a functional epitope on the human beta 1-adrenergic receptor. J. Exp. Med. 1995;182:59&#x2013;65. doi: 10.1084/jem.182.1.59.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.182.1.59</ArticleId><ArticleId IdType="pmc">PMC2192084</ArticleId><ArticleId IdType="pubmed">7790824</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallukat G., Schimke I. Agonistic autoantibodies directed against G-protein-coupled receptors and their relationship to cardiovascular diseases. Semin. Immunopathol. 2014;36:351&#x2013;363. doi: 10.1007/s00281-014-0425-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00281-014-0425-9</ArticleId><ArticleId IdType="pubmed">24777744</ArticleId></ArticleIdList></Reference><Reference><Citation>Aplin M., Bonde M.M., Hansen J.L. Molecular determinants of angiotensin II type 1 receptor functional selectivity. J. Mol. Cell. Cardiol. 2009;46:15&#x2013;24. doi: 10.1016/j.yjmcc.2008.09.123.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yjmcc.2008.09.123</ArticleId><ArticleId IdType="pubmed">18848837</ArticleId></ArticleIdList></Reference><Reference><Citation>Lukitsch I., Kehr J., Chaykovska L., Wallukat G., Nieminen-Kelh&#xe4; M., Batuman V., Dragun D., Gollasch M. Renal ischemia and transplantation predispose to vascular constriction mediated by angiotensin II type 1 receptor-activating antibodies. Transplantation. 2012;94:8&#x2013;13. doi: 10.1097/TP.0b013e3182529bb7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TP.0b013e3182529bb7</ArticleId><ArticleId IdType="pubmed">22691955</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallukat G., Wollenberger A. Involvement of &#x3b2;2-Adrenergic Receptors in the Potentaion of the Chronotropic Action of Isoprenaline Evoked in Rocker-Cultured Neonatal Rat Heart Cells by Pyruvate and L (+) Lactate. Martinius Nijhoff Publishing; Boston, MA, USA: 1987.</Citation></Reference><Reference><Citation>Staudt Y., Mobini R., Fu M., Felix S.B., K&#xfc;hn J.P., Staudt A. Beta1-adrenoceptor antibodies induce apoptosis in adult isolated cardiomyocytes. Eur. J. Pharmacol. 2003;466:1&#x2013;6. doi: 10.1016/S0014-2999(03)01431-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0014-2999(03)01431-6</ArticleId><ArticleId IdType="pubmed">12679135</ArticleId></ArticleIdList></Reference><Reference><Citation>Jane-wit D., Altuntas C.Z., Johnson J.M., Yong S., Wickley P.J., Clark P., Wang Q., Popovi&#x107; Z.B., Penn M.S., Damron D.S., et al. Beta 1-adrenergic receptor autoantibodies mediate dilated cardiomyopathy by agonistically inducing cardiomyocyte apoptosis. Circulation. 2007;116:399&#x2013;410. doi: 10.1161/CIRCULATIONAHA.106.683193.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.106.683193</ArticleId><ArticleId IdType="pubmed">17620508</ArticleId></ArticleIdList></Reference><Reference><Citation>Haberland A., Wallukat G., Dahmen C., Kage A., Schimke I. Aptamer neutralization of beta1-adrenoceptor autoantibodies isolated from patients with cardiomyopathies. Circ. Res. 2011;109:986&#x2013;992. doi: 10.1161/CIRCRESAHA.111.253849.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCRESAHA.111.253849</ArticleId><ArticleId IdType="pubmed">21868696</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallukat G., Morwinski M., Kowal K., F&#xf6;rster A., Boewer V., Wollenberger A. Autoantibodies against the beta-adrenergic receptor in human myocarditis and dilated cardiomyopathy: Beta-adrenergic agonism without desensitization. Eur. Heart J. 1991;12((Suppl. D)):178&#x2013;181. doi: 10.1093/eurheartj/12.suppl_D.178.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/12.suppl_D.178</ArticleId><ArticleId IdType="pubmed">1717272</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallukat G., Fu M.L., Magnusson Y., Hjalmarson A., Hoebeke J., Wollenberger A. Agonistic effects of anti-peptide antibodies and autoantibodies directed against adrenergic and cholinergic receptors: Absence of desensitization. Blood Press. Suppl. 1996;3:31&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">8973766</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallukat G., Fu H.M., Matsui S., Hjalmarson A., Fu M.L. Autoantibodies against M2 muscarinic receptors in patients with cardiomyopathy display non-desensitized agonist-like effects. Life Sci. 1999;64:465&#x2013;469. doi: 10.1016/S0024-3205(98)00589-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0024-3205(98)00589-X</ArticleId><ArticleId IdType="pubmed">10069511</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallukat G., Pruss H., Muller J., Schimke I. Functional autoantibodies in patients with different forms of dementia. PLoS ONE. 2018;13:e0192778. doi: 10.1371/journal.pone.0192778.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0192778</ArticleId><ArticleId IdType="pmc">PMC5851545</ArticleId><ArticleId IdType="pubmed">29538413</ArticleId></ArticleIdList></Reference><Reference><Citation>Sterin-Borda L., Perez Leiros C., Wald M., Cremaschi G., Borda E. Antibodies to beta 1 and beta 2 adrenoreceptors in Chagas&#x2019; disease. Clin. Exp. Immunol. 1988;74:349&#x2013;354.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1542036</ArticleId><ArticleId IdType="pubmed">2853016</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein-Weigel P.F., Bimmler M., Hempel P., Sch&#xf6;pp S., Dreusicke S., Valerius J., Bohlen A., Boehnlein J.M., Bestler D., Funk S., et al. G-protein coupled receptor auto-antibodies in thromboangiitis obliterans (Buerger&#x2019;s disease) and their removal by immunoadsorption. Vasa. 2014;43:347&#x2013;352. doi: 10.1024/0301-1526/a000372.</Citation><ArticleIdList><ArticleId IdType="doi">10.1024/0301-1526/a000372</ArticleId><ArticleId IdType="pubmed">25147011</ArticleId></ArticleIdList></Reference><Reference><Citation>Werner C., M&#xfc;ller N., M&#xfc;ller U.A. Agonistic autoantibodies against B2-adrenergic receptors correlating with macrovascular disease in longstanding diabetes type 2. Acta Diabetol. 2019;56:659&#x2013;665. doi: 10.1007/s00592-019-01296-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00592-019-01296-8</ArticleId><ArticleId IdType="pubmed">30770998</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallukat G., Wollenberger A. Effects of the serum gamma globulin fraction of patients with allergic asthma and dilated cardiomyopathy on chronotropic beta adrenoceptor function in cultured neonatal rat heart myocytes. Biomed. Biochim. Acta. 1987;46:S634&#x2013;S639.</Citation><ArticleIdList><ArticleId IdType="pubmed">2449194</ArticleId></ArticleIdList></Reference><Reference><Citation>Wenzel K., Schulze-Rothe S., Haberland A., M&#xfc;ller J., Wallukat G., Davideit H. Performance and in-house validation of a bioassay for the determination of beta1-autoantibodies found in patients with cardiomyopathy. Heliyon. 2017;3:e00362. doi: 10.1016/j.heliyon.2017.e00362.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.heliyon.2017.e00362</ArticleId><ArticleId IdType="pmc">PMC5541141</ArticleId><ArticleId IdType="pubmed">28795160</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallukat G., Wenzel K., Schimke I. Analytics of Functional Autoantibodies in Patients with Chagas Disease. Methods Mol. Biol. 2019;1955:247&#x2013;261. doi: 10.1007/978-1-4939-9148-8_19.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-4939-9148-8_19</ArticleId><ArticleId IdType="pubmed">30868533</ArticleId></ArticleIdList></Reference><Reference><Citation>Mardin C.Y., Schottenhamml J., Fassihi Dehcordi S., Mueller M., Maier A.K., Hohberger B. &#x2018;APSifyed&#x2019; Bruch&#x2019;s membrane opening (BMO) based peripapillary OCT-A analysis. Investig. Ophthalmol. Vis. Sci. 2021;62:3369.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>